Jyong Biotech Ltd. Ordinary Shares (MENS) Stock Score, Valuation & Financial Research

Jyong Biotech Ltd. Ordinary Shares is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for MENS

Jyong Biotech Ltd. Ordinary Shares does not currently have a complete Wall Street Score. The stored market price is USD 2.16. These figures are a research snapshot, not a buy or sell recommendation.

What Jyong Biotech Ltd. Ordinary Shares does

Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Jyong Biotech Ltd. is a science-driven biotechnology company that focuses on the research, development, and commercialization of innovative plant-derived therapeutics. The company generates value by advancing drug candidates through clinical development stages, primarily targeting urinary system diseases, and intends to monetize these assets through future commercial sales or licensing agreements.

Products and services

  • The company specializes in plant-derived pharmaceutical preparations, specifically focusing on therapeutics for urinary system diseases.

Customer types

Healthcare providers and patients.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company engages various unnamed third-party CROs to conduct clinical trials and research activities. Source

Business strengths to evaluate

  • Specialized focus on plant-derived therapeutics for urinary system diseases Source

Business risks and research considerations

  • Dependence on clinical trial success and regulatory approval processes Source
  • Reliance on third-party contract research organizations for development activities Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

MENS financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 2.16
Market capitalization:
164.22M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -4.67M
Free cash flow:
USD -3.04M
Cash:
USD 1.18M
Total debt:
USD 18.55M
EPS:
USD -0.10

What stands out

  • Free cash flow is USD -3.04M, negative for the stored period.
  • The balance sheet shows USD 1.18M of cash versus USD 18.55M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Debt exceeds cash by USD 17.37M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for MENS

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can MENS fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Is MENS's debt load manageable relative to cash generation, interest costs and upcoming maturities?
  • What specifically needs to improve for MENS to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of MENS's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-05.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research MENS

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.